Authors:
Address: Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Journal:

Publication:
Free Text: Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

abstract

BACKGROUND:

Lack of functional CCR5 increases the severity of certain viral infections, including West Nile virus and tickborne encephalitis. In a phase II trial of the investigational CCR5 antagonist vicriviroc (AIDS Clinical Trials Group protocol A5211), 4 Lymphomas occurred in study patients who received vicriviroc. Because of the known association between unregulated Epstein-Barr virus (EBV) replication and lymphoma in immunocompromised patients, we evaluated whether vicriviroc exposure was associated with lymphoma EBV antigen positivity and/or had an effect on plasma levels of EBV DNA.

METHODS:

Clinical findings for all 4 patients enrolled in the A5211 study who developed lymphoma (2 Hodgkin and 2 non-Hodgkin) were reviewed, and tumor specimens were assessed for evidence of ongoing EBV replication. Longitudinal plasma samples from 116 patients in the A5211 study were analyzed, and EBV DNA was quantified by real-time polymerase chain reaction.

results:

Plasma EBV DNA was not detected in the 2 patients with non-Hodgkin lymphoma; both patients with Hodgkin lymphoma who had samples tested had EBV DNA levels <3200 copies/mL. One patient with Hodgkin lymphoma had a lymph node core biopsy specimen that was strongly positive for EBV; the other 3 lymphomas were histochemically EBV negative. None of the 116 patients with available samples experienced sustained increases in plasma EBV levels.

CONCLUSIONS:

CCR5 antagonism by vicriviroc treatment in treatment-experienced patients was not associated with reactivation of EBV infection.

Related Articles
Epstein-Barr viral load as a marker of lymphoma in AIDS patients.
J Med Virol. 2005
Epstein-Barr viral load as a marker of lymphoma in AIDS patients.
Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, Elmore S, Moore DT, Schichman SA, Swinnen LJ, et al. J Med Virol. 2005 Jan; 75(1):59-69.
Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma.
J Neurovirol. 2002
Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma.
Bossolasco S, Cinque P, Ponzoni M, Vigano MG, Lazzarin A, Linde A, Falk KI. J Neurovirol. 2002 Oct; 8(5):432-8.
Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients.
APMIS. 2011
Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients.
Spacek M, Hubacek P, Markova J, Zajac M, Vernerova Z, Kamaradova K, Stuchly J, Kozak T. APMIS. 2011 Jan; 119(1):10-6. Epub 2010 Oct 25.
Review Epstein-Barr viral load measurement as a marker of EBV-related disease.
Mol Diagn. 2001
Review Epstein-Barr viral load measurement as a marker of EBV-related disease.
Fan H, Gulley ML. Mol Diagn. 2001 Dec; 6(4):279-89.
Review [Lymphoid malignancies: progress in diagnosis and treatment. Topics: I. Pathogenesis and pathophysiology--recent findings; 4. lymphoid malignancies and vires].
Nihon Naika Gakkai Zasshi. 2011
Review [Lymphoid malignancies: progress in diagnosis and treatment. Topics: I. Pathogenesis and pathophysiology--recent findings; 4. lymphoid malignancies and vires].
Tsukasaki K. Nihon Naika Gakkai Zasshi. 2011 Jul 10; 100(7):1781-6.
Review Clinical use of CCR5 inhibitors in HIV and beyond.
J Transl Med. 2011
Review Clinical use of CCR5 inhibitors in HIV and beyond.
Gilliam BL, Riedel DJ, Redfield RR. J Transl Med. 2011 Jan 27; 9 Suppl 1:S9. Epub 2011 Jan 27.
Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.
AIDS Res Ther. 2010
Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.
Huhn GD, Badri S, Vibhakar S, Tverdek F, Crank C, Lubelchek R, Max B, Simon D, Sha B, Adeyemi O, et al. AIDS Res Ther. 2010 Dec 14; 7:44. Epub 2010 Dec 14.
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
J Acquir Immune Defic Syndr. 2...
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajicic N, Goodrich J. J Acquir Immune Defic Syndr. 2010 Dec 15; 55(5):558-64.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster